1. Home
  2. KALU vs CDNA Comparison

KALU vs CDNA Comparison

Compare KALU & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kaiser Aluminum Corporation

KALU

Kaiser Aluminum Corporation

HOLD

Current Price

$121.82

Market Cap

1.9B

Sector

Industrials

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$19.10

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALU
CDNA
Founded
1946
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.0B
IPO Year
1991
2014

Fundamental Metrics

Financial Performance
Metric
KALU
CDNA
Price
$121.82
$19.10
Analyst Decision
Buy
Buy
Analyst Count
3
7
Target Price
$95.67
$26.67
AVG Volume (30 Days)
207.3K
765.6K
Earning Date
02-18-2026
02-25-2026
Dividend Yield
2.52%
N/A
EPS Growth
58.01
N/A
EPS
5.17
1.22
Revenue
$3,209,400,000.00
$357,998,000.00
Revenue This Year
$12.83
$14.11
Revenue Next Year
$12.98
$11.75
P/E Ratio
$23.65
$15.48
Revenue Growth
7.69
14.46
52 Week Low
$46.81
$10.96
52 Week High
$124.27
$25.95

Technical Indicators

Market Signals
Indicator
KALU
CDNA
Relative Strength Index (RSI) 76.09 51.15
Support Level $114.83 $18.75
Resistance Level $124.27 $20.13
Average True Range (ATR) 3.09 0.77
MACD 0.05 -0.19
Stochastic Oscillator 84.66 51.61

Price Performance

Historical Comparison
KALU
CDNA

About KALU Kaiser Aluminum Corporation

Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: